Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.

Siegenthaler, F; Lindemann, K; Epstein, E; Rau, T T; Nastic, D; Ghaderi, M; Rydberg, F; Mueller, M D; Carlson, J; Imboden, S (2022). Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification. Gynecologic oncology, 165(2), pp. 230-238. Elsevier 10.1016/j.ygyno.2022.02.024

[img]
Preview
Text
1-s2.0-S0090825822001433-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (614kB) | Preview

OBJECTIVE

Despite its generally favorable prognosis at primary diagnosis, recurrence of endometrial cancer remains an important clinical challenge. The aim of this study was to analyze the value of molecular classification in recurrent endometrial cancer.

METHODS

This study included patients with recurrent endometrial cancer who underwent primary surgical treatment between 2004 and 2015 at the Karolinska University Hospital, Sweden and the Bern University Hospital, Switzerland (KImBer cohort) with molecular classification of the primary tumor.

RESULTS

Out of 594 molecularly classified endometrial cancer patients, 101 patients experienced recurrence, consisting of 2 POLEmut, 33 MMRd, 30 p53abn, and 36 NSMP tumors. Mean age at recurrence was 71 years and mean follow-up was 54 months. Overall, median time to first recurrence was 16 months (95% CI 12-20); with the shortest median time in MMRd patients, with 13 months (95% CI 5-21). The pattern of recurrence was distinct among molecular subgroups: MMRd tumors experienced more locoregional, while p53abn cases showed more abdominal recurrences (P = .042). Median survival after recurrence was best for MMRd cases (43 months, 95% CI 11-76), compared to 39 months (95% CI 21-57) and 10 months (95% CI 7-13) for the NSMP and p53abn cases respectively (log-rank, P = .001).

CONCLUSION

Molecular classification is a significant indicator of survival after recurrence in endometrial cancer patients, and patterns of recurrence differ by molecular subgroups. While MMRd endometrial cancer show more locoregional recurrence and the best survival rates after recurrence, p53abn patients experience abdominal recurrence more often and had the worst prognosis of all recurrent patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Siegenthaler, Franziska Anna; Rau, Tilman; Mueller, Michael and Imboden, Sara

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

1095-6859

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

15 Mar 2022 12:19

Last Modified:

05 May 2022 00:14

Publisher DOI:

10.1016/j.ygyno.2022.02.024

PubMed ID:

35277281

Uncontrolled Keywords:

Endometrial cancer Molecular classification Pattern of recurrence Survival after recurrence Time to first recurrence

BORIS DOI:

10.48350/167391

URI:

https://boris.unibe.ch/id/eprint/167391

Actions (login required)

Edit item Edit item
Provide Feedback